Travere Q1: FILSPARI sales $19.8M; FDA Priority Review for full approval by Sept 5

Travere Therapeutics, Inc.

2024-Q1 EPS reported -$1.76 revenue$41,374,000

Net product sales $40.0M (Q1 2024), up from $24.2M YoY, driven by FILSPARI launch.
FILSPARI net sales $19.8M; 511 new PSFs in Q1, total 1,963 since launch.
FDA granted Priority Review for sNDA to convert accelerated approval to full approval for IgAN; PDUFA Sept 5, 2024.
Net loss $136.1M ($1.76/share) vs $86.3M loss in Q1 2023, including $65M IPR&D milestone for pegtibatinase.
Cash, equivalents, and securities $441.0M as of March 31, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Travere Therapeutics, Inc. reported the first quarter of 2024 results: revenue $40.0 million, net income $136.1 million, or $1.76 per basic share, EPS $1.76 per basic share.

Period: the first quarter of 2024
Revenue: $40.0 million
Net income: $136.1 million, or $1.76 per basic share
EPS: $1.76 per basic share
Result: reported results

Exact text from the filing

Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-24-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.